CTI BioPharma Initiates Rolling Submission of U.S. NDA for Pacritinib for Treatment of Patients with Myelofibrosis

CTI BioPharma Corp. (NASDAQ: CTIC) announced the initiation of its rolling new drug application (NDA) to the U.S. Food and Drug ...